Compare RVSN & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSN | ATHA |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 18.2M |
| IPO Year | 2022 | 2020 |
| Metric | RVSN | ATHA |
|---|---|---|
| Price | $0.38 | $7.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 734.0K | ★ 3.1M |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $776,000.00 | N/A |
| Revenue This Year | $28.46 | N/A |
| Revenue Next Year | $755.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $2.20 |
| 52 Week High | $2.72 | $8.36 |
| Indicator | RVSN | ATHA |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 79.95 |
| Support Level | $0.33 | $6.37 |
| Resistance Level | $0.37 | $8.36 |
| Average True Range (ATR) | 0.03 | 0.48 |
| MACD | 0.00 | 0.39 |
| Stochastic Oscillator | 55.94 | 74.78 |
Rail Vision Ltd is a development-stage technology company that is engaged in the design, development, and assembly of railway detection systems designed to solve the challenges in railway operational safety, efficiency, and predictive maintenance. Its railway detection systems include different types of cameras, including optics, visible light spectrum cameras (video), and thermal cameras that transmit data to a ruggedized onboard computer which is designed to be suitable for the rough environment of a train's locomotive. It has developed its railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operator.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.